You're signed outSign in or to get full access.
Kinnevik Ab (publ)
Kinnevik AB (publ) is a Swedish investment company headquartered in Stockholm, founded in 1936 by the Stenbeck, Klingspor, and von Horn families. It is a leading growth investor, active owner, and operational partner, providing patient capital to challenger technology-enabled businesses in Europe and the US. Kinnevik focuses on investments within healthcare, software, marketplaces, and climate tech, and serves a global investor base through large cap listing on Nasdaq Stockholm. The firm employs around 60 people and supports founders building transformative companies with a long-term philosophy.
Investment Strategy
Kinnevik is a long-term, active owner investing predominantly in disruptive, technology-enabled businesses within healthcare, software, and climate sectors, with a focus on Europe and the US. The firm provides patient capital, partnering across all growth stages to back founders who aim to redefine industries and foster significant market opportunities. Kinnevik acts as an operational partner, focusing on value creation through supporting organic and inorganic growth, and maintains a disciplined approach toward sustained profitability and industry disruption.
Latest 13F Filing Activity
Kinnevik Ab (publ) filed their most recent 13F report on Jun 30, 2025 disclosing 1 equity positions with a total 13F market value of $68M. The fund increased holdings in Recursion Pharmaceuticals, Inc.. Kinnevik Ab (publ) reduced exposure to Recursion Pharmaceuticals, Inc..
Top Holdings
Equity Positions (1)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
R RXRX | Recursion Pharmaceuticals, Inc. | 100.00% | $68.0M | 13,434,171 | $7.36 | $5.06 | -$3.1M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more